BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Clinical Trials
216
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (214 trials with phase data)• Click on a phase to view related trials
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
- Conditions
- Solid TumorsAdvanced Solid Tumor
- Interventions
- Drug: BG-C0902
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 63
- Registration Number
- NCT07181681
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
- Conditions
- Waldenström's Macroglobulinemia
- Interventions
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 18
- Registration Number
- NCT07169331
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- BeOne Medicines
- Target Recruit Count
- 24
- Registration Number
- NCT07141511
- Locations
- 🇦🇺
Linear Early Phase, Joondalup, Western Australia, Australia
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-11-21
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 90
- Registration Number
- NCT07100938
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Metastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Subcutaneous TislelizumabDrug: Intravenous Tislelizumab
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-11-21
- Lead Sponsor
- BeOne Medicines
- Target Recruit Count
- 351
- Registration Number
- NCT07043400
- Locations
- 🇺🇸
Nebraska Hematology Oncology, Lincoln, Nebraska, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 34
- Next
News
Gastric Cancer Pipeline Shows Robust Growth with 220+ Therapies in Development Across 200+ Companies
DelveInsight's 2025 pipeline report reveals over 200 companies developing 220+ therapeutic candidates for gastric cancer treatment across all clinical stages.
Follicular Lymphoma Market Poised for 6% CAGR Growth Through 2034 as Novel Therapies Advance
The follicular lymphoma market is projected to grow at a 6% CAGR during 2025-2034, driven by increased disease awareness and rising number of clinical trials focused on this slow-growing B-cell malignancy.
Targeted Protein Degradation Emerges as Multi-Billion Dollar Therapeutic Frontier with First PROTAC Approval Expected in 2026
Targeted protein degradation (TPD) has evolved from niche science to mainstream drug development, with over 40 PROTAC candidates in clinical testing and the first potential market approval expected for Arvinas/Pfizer's ARV-471 by June 2026.
Ascentage Pharma Strengthens Leadership Team with New CFO and Senior VP Appointments
Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.
AstraZeneca and Summit Therapeutics in Advanced Talks for $15 Billion Ivonescimab Licensing Deal
AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.
Glenmark Launches Tevimbra, First Immuno-Oncology Drug in India for Lung and Esophageal Cancer Treatment
Glenmark Pharmaceuticals has launched Tevimbra (tislelizumab), marking the company's first entry into immuno-oncology in India following CDSCO approval.
Tislelizumab Shows Promise as Adjuvant Therapy for High-Risk Hepatocellular Carcinoma Patients
A multicenter retrospective study of 108 patients demonstrated that tislelizumab, with or without tyrosine kinase inhibitors, significantly extended recurrence-free survival in high-risk hepatocellular carcinoma patients after curative resection.
Glenmark Pharmaceuticals Receives DCGI Approval to Launch BRUKINSA for Five B-Cell Malignancies in India
Glenmark Pharmaceuticals has received DCGI approval to launch zanubrutinib (BRUKINSA) in India, marking the first BTK inhibitor approved for treating five distinct B-cell malignancies.
Biocytogen Secures Japan Patent for RenMab Platform, Strengthening Global IP Portfolio for Fully Human Antibody Discovery
Biocytogen Pharmaceuticals has received a Japan Patent Office invention patent for its RenMab fully human antibody mouse platform technology, marking a significant milestone in global intellectual property expansion.
CSPC Pharmaceutical Announces Potential $5 Billion Drug Licensing Deals Following Q1 Revenue Decline
CSPC Pharmaceutical Group revealed it is in talks with three parties for licensing deals worth up to $5 billion in potential fees, including a targeted cancer therapy and other novel drug candidates.